fortune gems tricks
Pay first, deliver later: Some women are being asked to prepay for their baby
TALLAHASSEE, Fla. (AP) — Luke Kromenhoek threw for 209 yards and tossed three touchdown passes as Florida State halted a six-game losing streak and routed Charleston Southern 41-7 on Saturday. Kromenhoek completed 13 of 20 passes in his first college start, including a 71-yard touchdown pass to Ja’Khi Douglas, as the Seminoles (2-9) won for the first time since Sept. 21. The true freshman also connected with Amaree Williams for a 4-yard TD and Hykeem Williams for a 10-yard TD. “It was unbelievable, it was a dream come true,” Kromenhoek said. “The more snaps I get, the more reps that I get, it slows down little by little. I just try to take advantage of every one that I get.” The Seminoles (2-9) have started three quarterbacks and nine offensive line combinations this fall, and they came into Saturday with the nation’s worst scoring offense (13.3 points). Florida State hadn’t scored more than 21 points or surpassed the 300-yard mark in 2024. But Florida State overwhelmed FCS Charleston Southern (1-11), accumulating 415 offensive yards. Coach Mike Norvell made major changes following a 52-3 loss at Notre Dame on Nov. 9. He fired offensive coordinator/offensive line coach Alex Atkins, defensive coordinator Adam Fuller and wide receivers coach Ron Dugans. On Saturday, Norvell again called plays (as he has done throughout his five years at Florida State). Randy Shannon, the linebackers coach, was elevated to interim defensive coordinator. “It’s been a tough last couple weeks, tough season in general,” Norvell said. “But I was really proud of them for how they approached this week and the work that they poured in. From senior to freshman, there was a lot of investment to go push to be better.” After a scoreless first quarter, Florida State poured it on — scoring on six straight drives. This is the first time the Seminoles have scored 10 or more points in a quarter, tallying 17 in the second and 14 in the third. Kaleb Jackson completed 22 of 32 passes for 218 yards, including a 7-yard touchdown pass to Landon Sauers, and an interception for the Buccaneers. Next up: Randy Shannon Story continues below video Shannon stepped in to coordinate, guiding a first- and second-team defense that didn’t allow a point. Florida State led 31-0 after three quarters, allowing Charleston Southern to pick up just 124 offensive yards and holding the Buccaneers to 23 rushing yards. Once Miami’s head coach, Shannon has now been a defensive coordinator at all four of the state’s Power 4 schools. Shannon was the defensive coordinator at Miami (2001-06), Florida (2017), UCF (2018-20) and will now also be Florida State's interim coordinator next week against Florida. The takeaway Charleston Southern: While the Buccaneers found some success through the air, they couldn’t sustain drives and managed just 57 rushing yards on 29 carries. Florida State: The Seminoles picked up a season-best 176 rushing yards, scoring 17 points in the second quarter and 14 points in the third quarter to take control. Up next Charleston Southern’s season is over. Florida State plays host to Florida on Nov. 30. AP college football: https://apnews.com/hub/ap-top-25-college-football-poll and https://apnews.com/hub/college-football . Sign up for the AP’s college football newsletter: https://apnews.com/cfbtop25
Gary Neville says Ipswich played like they have a “better coach” in a scathing assessment of Ruben Amorim’s first game in charge of Manchester United. Marcus Rashford gave Amorim the dream start , scoring inside two minutes on Sunday, but the game finished 1-1 after Omari Hutchinson’s fine long-range strike levelled things up. Much has been made of Amorim’s switch to a 3-4-3 system and the new Red Devils boss insists his players will need time to adapt to the new setup. And as Jamie Carragher highlighted the “big problem” for Amorim , Neville claimed the “red flags” present under Erik ten Hag remain under the new manager. “I mean, the red flags that were there yesterday have probably been there in the last few months and the last season and a half,” Neville told Sky Sports. “It’s a team that is very difficult to actually like watching, and I say that with respect because I genuinely do believe what Ruben Amorim said at the end of the game. “No football player goes out onto the pitch and wants to lose or doesn’t want to win or work hard or do well. They don’t want criticism.” MORE MAN UTD COVERAGE ON F365... 👉 Amorim Watch: New Man Utd manager rubs his nose a lot and we get bored 👉 Mailbox: Ruben Amorim at Man Utd: ‘New Manager Thud anyone?’ 👉 Good luck Ruben Amorim; Man Utd are ‘a fat, lazy, bloated corpse of a club’ Neville went on to claim that 18th-placed Ipswich – managed by former United assistant Kieran McKenna – looked the better coached side. The former United defender continued: “But you watch them play, even yesterday, in the new system, and you look at Ipswich, who are very near the bottom of the league. “They looked more organised, [like they had a] better coach, they looked like they had more appetite for the game and more enthusiasm. “And that’s a constant, and it has been a constant, not just, obviously, on Sunday, but a constant for the last year and a half, two years, three years. “So we’ve got a situation where these group of players, to be honest with you, have created a pattern for themselves and become what they are. “And it wasn’t just a red flag yesterday because the same things that we’ve seen in the last six to eight months, 10 months, we saw yesterday. “With Ruben Amorim being the manager, he saw it as well. I think he obviously knew how big a job this was. I think he recognised that yesterday.” The Sky Sports pundit did though back United to improve under the Portuguese coach once more of his squad becomes available. He concluded: “It will get better in the next few weeks because, like you say, that back five that he picks, and I’m not talking about the actual wing-backs here. “I’m talking about the three at the back and the two in midfield. That will become more energetic and better when the personnel changes occur. “But there’s a long way to go. I think Roy [Keane] yesterday said that Manchester United were an average team, and that’s being kind.”
Trump Vows To Build More Monuments And People Have Thoughts
PNC Financial Services Group Inc. lifted its holdings in shares of Broadridge Financial Solutions, Inc. ( NYSE:BR – Free Report ) by 1.0% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 49,948 shares of the business services provider’s stock after purchasing an additional 504 shares during the quarter. PNC Financial Services Group Inc.’s holdings in Broadridge Financial Solutions were worth $10,740,000 at the end of the most recent quarter. Several other institutional investors also recently modified their holdings of BR. B. Metzler seel. Sohn & Co. Holding AG purchased a new position in shares of Broadridge Financial Solutions in the 3rd quarter worth about $44,746,000. Meeder Asset Management Inc. boosted its stake in Broadridge Financial Solutions by 0.4% in the third quarter. Meeder Asset Management Inc. now owns 41,583 shares of the business services provider’s stock worth $8,942,000 after buying an additional 176 shares in the last quarter. Caprock Group LLC grew its position in Broadridge Financial Solutions by 12.0% during the third quarter. Caprock Group LLC now owns 4,113 shares of the business services provider’s stock valued at $888,000 after acquiring an additional 440 shares during the last quarter. Pathstone Holdings LLC raised its stake in shares of Broadridge Financial Solutions by 0.4% during the third quarter. Pathstone Holdings LLC now owns 20,791 shares of the business services provider’s stock worth $4,473,000 after acquiring an additional 87 shares in the last quarter. Finally, Strengthening Families & Communities LLC lifted its holdings in shares of Broadridge Financial Solutions by 6.6% in the 3rd quarter. Strengthening Families & Communities LLC now owns 12,541 shares of the business services provider’s stock worth $2,697,000 after acquiring an additional 779 shares during the last quarter. 90.03% of the stock is currently owned by institutional investors. Broadridge Financial Solutions Trading Up 1.2 % Shares of BR opened at $230.24 on Friday. Broadridge Financial Solutions, Inc. has a 1-year low of $185.30 and a 1-year high of $230.30. The firm has a market capitalization of $26.91 billion, a price-to-earnings ratio of 39.83 and a beta of 1.05. The firm’s 50-day moving average price is $217.12 and its 200-day moving average price is $208.88. The company has a current ratio of 1.39, a quick ratio of 1.39 and a debt-to-equity ratio of 1.63. Broadridge Financial Solutions Dividend Announcement The firm also recently disclosed a quarterly dividend, which will be paid on Friday, January 3rd. Investors of record on Friday, December 13th will be paid a dividend of $0.88 per share. This represents a $3.52 annualized dividend and a yield of 1.53%. The ex-dividend date of this dividend is Friday, December 13th. Broadridge Financial Solutions’s payout ratio is currently 60.90%. Wall Street Analysts Forecast Growth Several analysts have issued reports on the stock. Royal Bank of Canada restated an “outperform” rating and set a $246.00 price target on shares of Broadridge Financial Solutions in a research report on Wednesday, November 6th. StockNews.com cut shares of Broadridge Financial Solutions from a “buy” rating to a “hold” rating in a report on Saturday, November 9th. UBS Group started coverage on shares of Broadridge Financial Solutions in a report on Thursday. They set a “neutral” rating and a $250.00 price target for the company. Morgan Stanley raised their price target on shares of Broadridge Financial Solutions from $200.00 to $207.00 and gave the stock an “equal weight” rating in a report on Wednesday, November 6th. Finally, JPMorgan Chase & Co. increased their target price on shares of Broadridge Financial Solutions from $224.00 to $225.00 and gave the stock a “neutral” rating in a report on Tuesday, August 20th. Five research analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. According to data from MarketBeat, the company has an average rating of “Hold” and a consensus price target of $222.43. View Our Latest Analysis on BR Insider Buying and Selling at Broadridge Financial Solutions In related news, Chairman Richard J. Daly sold 21,938 shares of the firm’s stock in a transaction that occurred on Friday, September 6th. The shares were sold at an average price of $207.66, for a total transaction of $4,555,645.08. Following the completion of the sale, the chairman now owns 105,094 shares of the company’s stock, valued at $21,823,820.04. This trade represents a 17.27 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website . Also, insider Douglas Richard Deschutter sold 24,185 shares of the company’s stock in a transaction that occurred on Thursday, November 7th. The shares were sold at an average price of $220.21, for a total value of $5,325,778.85. Following the completion of the transaction, the insider now directly owns 27,137 shares in the company, valued at $5,975,838.77. This trade represents a 47.12 % decrease in their ownership of the stock. The disclosure for this sale can be found here . Over the last quarter, insiders sold 84,033 shares of company stock valued at $18,149,572. Corporate insiders own 1.30% of the company’s stock. Broadridge Financial Solutions Profile ( Free Report ) Broadridge Financial Solutions, Inc provides investor communications and technology-driven solutions for the financial services industry. The company's Investor Communication Solutions segment processes and distributes proxy materials to investors in equity securities and mutual funds, as well as facilitates related vote processing services; and distributes regulatory reports, class action, and corporate action/reorganization event information, as well as tax reporting solutions. Recommended Stories Receive News & Ratings for Broadridge Financial Solutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Broadridge Financial Solutions and related companies with MarketBeat.com's FREE daily email newsletter .Nasdaq surges above 20,000 after US inflation data matches estimates
AI overload: Samsung just took the wraps off its new Galaxy Book 5 Pro laptop in South Korea and one thing was clear – the company is going all-in on AI. Not only does the laptop boast the kind of AI performance we've come to expect with Intel's new Lunar Lake chips, but it actually sports a bunch of built-in features to make use of it. Available in 14-inch and 16-inch sizes, the Galaxy Book 5 Pro models are powered by Intel's Core Ultra Processor Series 2 silicon. These devices feature 2.8K AMOLED displays with a 120Hz refresh rate. Additionally, Samsung's "Vision Booster" technology promises improved screen visibility, even in challenging lighting conditions. The laptops also come with quad speakers equipped with discrete tweeters and woofers, along with support for Dolby Atmos. The biggest draw, though, is the eye-popping 25-hour battery life estimate from Samsung. That's a notable step up over last year's Galaxy Book 4 Pro, which offered up to 21 hours of video runtime. Of course, since these are powered by Lunar Lake CPUs , they come with a dedicated NPU capable of delivering 47 TOPS of AI performance. To make use of this, Samsung has baked AI features throughout the software experience. One such feature is AI Select, which lets you circle any on-screen element to instantly search the web for information about it. Users can also use it to select text from images and scan QR codes. This laptop is actually the first to gain this feature, which is borrowed from Google's new Circle to Search available on Galaxy phones. The laptop's webcam gets an AI boost, too, with a special HDR mode that combines multiple exposure levels into one vibrant, high-dynamic range image. Samsung says this results in superior color accuracy and clarity compared to standard webcams. AI also plays a role in the Photo Remaster utility, which can upscale and enhance low-resolution images. Beyond these features, you get the run-of-the-mill features we've come to expect with the so-called Microsoft Copilot+ PCs, like local AI photo and video editing. However, some details remain unclear. Samsung has not disclosed specifics regarding pricing, memory, or storage options. What we do know is that the laptop will launch in South Korea on January 2, 2024, and will be available in gray and silver. The company has also been tight-lipped about international availability. One possibility could be a CES 2025 unveil as soon as next month, though if past Galaxy Book releases are any indication, a global rollout might follow by mid-2025.
Corey puts up 27 and South Alabama knocks off East Texas A&M 81-72A surge in mysterious drone sightings across New Jersey and neighboring states has ignited public concern and federal scrutiny. For almost a month, residents have reported hundreds of enormous drones, six feet in diameter, flying from sundown till 11 p.m. New York and Maryland have also reported sightings, which has increased conjecture. On Thursday, the Department of Homeland Security (DHS) and the FBI jointly released a statement discussing the situation. They said there was no proof that the drones were a threat to public safety or national security. They did point out that many encounters included legally flying manned aircraft, though. “The FBI, DHS, and our federal partners, in coordination with New Jersey State Police, continue to deploy resources,” the statement read. “Efforts are underway to confirm if these flights involve drones, manned aircraft, or false reports.” Allegations of Nuclear LinksSuspicions were heightened by a viral video that Colin Rugg shared on the social networking platform X, which was formerly Twitter. An unidentified drone maker said in the film that the drones may be looking for a nuclear bomb from Ukraine that has gone missing. According to the person, more than 80 Ukrainian warheads disappeared during the 1980s as part of nuclear disarmament efforts by Ronald Reagan. Additionally, he claimed to have just met someone who handled one of these warheads in person. The unidentified insider speculated that this bomb could have been headed for the US. “He physically touched this warhead... and knew it was heading here,” he said. Trump Demands ActionDonald Trump, the president-elect, demanded on Friday that the government take swift, decisive action or immediately increase openness. He voiced doubts about the government's lack of engagement in the issue in a piece published on Truth Social. “Mystery drone sightings all over the country. Can this really be happening without our government’s knowledge? I don’t think so!” he wrote. “Let the public know, and now. Otherwise, shoot them down!” This was the most forceful remark on the subject made by a prominent figure to date. Lawmakers Demand TransparencyLawmakers from New Jersey joined the increasing outcry demanding answers. New York Senators Chuck Schumer and Kristen Gillibrand, together with Senators Cory Booker and Andy Kim, called on government agencies to move quickly. They sought a briefing on attempts to identify and address the drone sightings in a letter to the Federal Aviation Administration, the FBI, and DHS. The letter demanded openness and emphasized popular outrage over the mysterious flights. Unanswered QuestionsFederal officials have reassured people, but the mysterious planes have caused a great deal of anxiety. Investigations are still underway, according to officials, and staff and technology are being used to find the facts. The public is still hearing theories about anything from innocuous civilian operations to reconnaissance missions. But the absence of conclusive responses has only increased apprehension and conjecture. Get Latest News Live on Times Now along with Breaking News and Top Headlines from US News, World and around the world.
SAN DIEGO , Dec. 10, 2024 /PRNewswire/ -- Realty Income Corporation (Realty Income, NYSE: O), The Monthly Dividend Company ® , today announced it has declared an increase in the company's common stock monthly cash dividend to $0.2640 per share from $0.2635 per share. The dividend is payable on January 15, 2025 , to stockholders of record as of January 2, 2025 . This is the 128 th dividend increase since Realty Income's listing on the NYSE in 1994. The new monthly dividend represents an annualized dividend amount of $3.168 per share as compared to the prior annualized dividend amount of $3.162 per share. "Throughout our 55-year history, Realty Income has declared 654 consecutive monthly dividends," said Sumit Roy , Realty Income's President and Chief Executive Officer. "Today's declaration represents the 109 th consecutive quarter that we have declared a dividend increase since our 1994 NYSE listing, demonstrating our commitment to providing stockholders a dependable monthly dividend that increases over time." About Realty Income Realty Income (NYSE: O), an S&P 500 company, is real estate partner to the world's leading companies. Founded in 1969, we invest in diversified commercial real estate and have a portfolio of over 15,450 properties in all 50 U.S. states, the U.K., and six other countries in Europe . We are known as "The Monthly Dividend Company ® ," and have a mission to invest in people and places to deliver dependable monthly dividends that increase over time. Since our founding, we have declared 654 consecutive monthly dividends and are a member of the S&P 500 Dividend Aristocrats ® index for having increased our dividend for the last 30 consecutive years. Additional information about the company can be found at www.realtyincome.com . Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Exchange Act of 1934, as amended. When used in this press release, the words "estimated," "anticipated," "expect," "believe," "intend," "continue," "should," "may," "likely," "plans," and similar expressions are intended to identify forward-looking statements. Forward-looking statements include discussions of our business and portfolio; cash flows; the intentions of management; and dividends, including the amount, timing and payment of dividends related thereto. Forward-looking statements are subject to risks, uncertainties, and assumptions about us, which may cause our actual future results to differ materially from expected results. Some of the factors that could cause actual results to differ materially are, among others, our continued qualification as a real estate investment trust; general domestic and foreign business, economic, or financial conditions; competition; fluctuating interest and currency rates; inflation and its impact on our clients and us; access to debt and equity capital markets and other sources of funding (including the terms and partners of such funding); continued volatility and uncertainty in the credit markets and broader financial markets; other risks inherent in the real estate business including our clients' solvency, client defaults under leases, increased client bankruptcies, potential liability relating to environmental matters, illiquidity of real estate investments, and potential damages from natural disasters; impairments in the value of our real estate assets; changes in domestic and foreign income tax laws and rates; property ownership through joint ventures, partnerships and other arrangements which may limit control of the underlying investments; epidemics or pandemics, including measures taken to limit their spread, the impacts on us, our business, our clients, and the economy generally; the loss of key personnel; the outcome of any legal proceedings to which we are a party or which may occur in the future; acts of terrorism and war; the anticipated benefits from mergers and acquisitions including from the merger with Spirit Realty Capital, Inc.; and those additional risks and factors discussed in our reports filed with the U.S. Securities and Exchange Commission. Readers are cautioned not to place undue reliance on forward-looking statements. Forward-looking statements are not guarantees of future plans and performance and speak only as of the date of this press release. Actual plans and operating results may differ materially from what is expressed or forecasted in this press release and forecasts made in the forward-looking statements discussed in this press release might not materialize. We do not undertake any obligation to update forward-looking statements or publicly release the results of any forward-looking statements that may be made to reflect events or circumstances after the date these statements were made. View original content to download multimedia: https://www.prnewswire.com/news-releases/128th-common-stock-monthly-dividend-increase-declared-by-realty-income-302328137.html SOURCE Realty Income Corporation
Federal response to mysterious drone sightings draws bipartisan criticism
Salasi Lanka Engineering Services Limited is planning to invest around Rs. 250 million to set up a plant to locally manufacture water proofing material, concrete grout and several similar products in Sri Lanka. This will be as a joint venture with ARDEX-QUICSEAL Singapore Pte. Ltd. a wholly-owned subsidiary of ARDEX GmbH, Germany. Salasi Lanka Chairman U. A. Padukka said that they will use local rubber and most of the other locally sourced raw material for this venture where the value addition would be over 60%. “We also hope to engage in exports,” he said. Padukka said that they had this plan for the last three years but had to put it on hold due to the COVID pandemic and the economic crisis that followed. “We now see a better investment climate in the country to launch an operation of this nature.” Salasi Lanka (Private) Limited established Salasi Lanka Engineering Services (Private) Limited in year 2009 with the objective of providing engineering services for the works and this newly established company has provided its contribution to many gigantic projects in the construction field in this country including Havelock City, several star class hotels and for many landmark building in both the government and private sector. With the advance of mobile technology and to cater to customers online we launched their website, www.sles.lk last week at its Head Office premises at, Maradana, Colombo. “Through this web, customers can access the range of services offered by Salasi Lanka Engineering Services relevant to the construction field and even order products and get technical advice and even quotations for projects.” A leading private company engaged in the construction field since the year 2000 has won the Construction Excellence Award in 2017, offered by CIDA. Padukka explained that through the launching of this website, customers can obtain the services from his companies without calling over at the companies, and to know about the projects relevant to the construction field and to obtain instructions regarding various items marketed by his companies. Ardex Quickseal Singapore Zonal Business Promotion Manageress Teresa Lim, said that they work very closely with Salasi Lanka Business Group of Companies. “Our products are sold all over Asia and hence they match the Sri Lankan weather conditions as well.” (SS)Advancements in Wireless Communication Propel RF Antennas Market to $6.4 Billion by 2034 | TMR
NoneREBEKAH Vardy has hit back at Iain Lee after he made a series of claims about their time together on I'm A Celebrity. The TV star and Sun columnist has rubbished former radio host Iain's claims she 'bullied' him in the jungle, leading to him to quit the industry for good. Iain, 51 , said he was subjected to multiple foul-mouthed exchanges from Vardy, 42 , during their stint Down Under in 2017. He told MailOnline : "When I was on the show, she bullied me and led a clique that picked on me. There were two occasions when I wanted to get out, it was so toxic and dark in there. I thought: 'I can’t be with these people.' I don’t watch the show now because of what I experienced." However, mum-of-five Becky has hit back in defence, by publishing their private WhatsApp conversations after they left the jungle. In the messages, which she posted to Instagram, she offered him supportive words of encouragement as he struggled following jungle life. more on rebekah vardy Iain told Becky in their exchange that he didn't think she was a bully, adding: "I have no bad feelings towards you. You're pretty amazing." Becky also said she had "no bad feelings" towards Iain. In another screenshot, the star confronted Iain over his previous comments about her and how she had threatened to 'sue' him. Replying, Iain said "I'm sorry about this" before deleting his tweets about her and offered Becky a 'Twitter apology'. Most read in I’m A Celebrity 2024 She also pleaded with him: "You know you are lying about things... You are inciting bullying this has to stop I have all the messages between us that contradict your ridiculous claims." Iain added to the MailOnline: "My experience in the jungle led me to change career and become a counsellor. I started seeing a great therapist and work through what happened to me. "When I came out of the show I was not all right. It sent me into a spiral of depression and anxiety. It really upset me." Meanwhile, Becky, who is The Sun's I'm A Celebrity columnist said how this year's show needs more drama and entertainment. She said: "Barry’s still being a true gent offering to run Danny a bath. "He’s just so sweet and he’s definitely providing the entertainment at the minute talking about his boxing career and his boxing knowledge. "Who knows? Maybe he could set up a ring in the camp and get them all fighting?" i'm A Celebrity is back for its 24th series, with a batch of famous faces living in the Aussie jungle. The Sun's Jake Penkethman takes a look at the stars on the show this year.. Coleen Rooney - Arguably the most famous name in the camp, the leading WAG, known for her marriage to Wayne Rooney , has made a grand return to TV as she looks to put the Wagatha Christie scandal behind her. The Sun revealed the mum-of-four had bagged an eye-watering deal worth over £1.5million to be on the show this year making her the highest-paid contestant ever. Tulisa - The popstar and former X Factor judge has made her triumphant TV comeback by signing up to this year's I'm A Celeb after shunning TV shows for many years. Known for being a member of the trio, N-Dubz , Tulisa became a household name back in 2011 when she signed on to replace Cheryl on ITV show The X Factor in a multi-million pound deal. Alan Halsall - The actor, known for playing the long-running role of Tyrone Dobbs on ITV soap opera Coronation Street , was originally signed up to head Down Under last year but an operation threw his scheduled appearance off-course. Now he has become the latest Corrie star to win over both the viewers and his fellow celebrities. Melvin Odoom - The Radio DJ has become a regular face on TV screens after rising to fame with presenting roles on Kiss FM, BBC Radio 1 and 4Music. Melvin has already been for a spin on the Strictly dancefloor and co-hosted The Xtra Factor with Rochelle Humes in 2015 but now he is facing up to his biggest challenge yet - the Aussie jungle . GK Barry - The UK's biggest social media personality, GK, whose real name is Grace Keeling, has transformed her TikTok stardom into a lucrative career. Aside from her popular social media channels, she hosts the weekly podcast, Saving Grace, and regularly appears on ITV talk show, Loose Women . She has even gone on to endorse popular brands such as PrettyLittleThing, KFC and Ann Summers. Dean McCullough - A rising star amongst this year's bunch of celebs , Dean first achieved notability through his radio appearances on Gaydio and BBC Radio 1. He was chosen to join the BBC station permanently in 2021 and has featured prominently ever since. He has enjoyed a crossover to ITV over the past year thanks to his guest slots on Big Brother spin-off show, Late & Live. Oti Mabuse - The pro dancer has signed up to her latest TV show after making her way through the biggest programmes on the box. She originally found fame on Strictly Come Dancing but has since branched out into the world of TV judging with appearances on former BBC show The Greatest Dancer as well as her current role on ITV's Dancing On Ice . Danny Jones - The McFly star was drafted into the programme last minute as a replacement for Tommy Fury. Danny is the second member of McFly to enter the jungle , after Dougie Poynter won the show in 2011. He is also considered a rising star on ITV as he's now one of the mentors on their Saturday night talent show, The Voice , along with bandmate Tom Fletcher . Jane Moore - The Loose Women star and The Sun columnist is braving the creepy crawlies this year. The star is ready for a new challenge - having recently split from her husband . It will be Jane's first foray into reality TV with the telly favourite having always said no to reality shows in the past. Barry McGuigan - Former pro boxer Barry is the latest fighting champ to head Down Under following in the footsteps of Tony Bellew and Amir Khan . It comes after a tough few years for Irish star Barry, who lost his daughter Danika to bowel cancer . He told The Late Late Show in 2021: "She was such an intrinsic part of the family that every day we ache." Maura Higgins - The Irish TV beauty first found fame on Love Island where she found a brief connection with dancer Curtis Pritchard . Since then, she has competed on Dancing On Ice as well as hosting the Irish version of the beauty contest, Glow Up. Since last year, she has been working on building up her career in the US by being the social media correspondent and host of Aftersun to accompany Love Island USA. She even guest hosted an episode of the spin-off, Love Island Games, in place of Maya Jama last year. Rev. Richard Coles - Former BBC radio host the Rev Richard Coles is a late arrival on I’m A Celebrity , and he's ready to spill the beans on his former employer. The former Communards and Strictly star , said the BBC did not know its a**e from its elbow last year. An insider said: "Rev Coles will have a variety of tales to tell from his wild days as a pop star in the Eighties, through to performing on Strictly and his later life as a man of the cloth."OXFORD, Ohio (AP) — Kam Craft's 34 points led Miami (OH) over Bethany (WV) 112-70 on Sunday. Craft had a big night from beyond the arc for the RedHawks (6-3), as he made 10 of Miami's 22 3-pointers. Brant Byers scored 21 points while going 8 of 10 (5 for 7 from 3-point range). Eian Elmer had 20 points and shot 7 for 13, including 4 for 7 from beyond the arc. Ben Guffey led the way for the Bison with 12 points. Troy Hixson added 11 points for Bethany. Cole Dailey finished with 10 points. Miami took the lead with 19:17 left in the first half and did not relinquish it. The score was 62-28 at halftime, with Byers racking up 17 points. Miami outscored Bethany by eight points in the second half, and Craft scored a team-high 20 points in the second half to help secure the victory. The Associated Press created this story using technology provided by Data Skrive and data from Sportradar .
CDC chief urges focus on health threats as agency confronts political changesGoogle's New Computer Chip May Tap 'Multiversal' Power to Function Billions of Times Faster than Supercomputers; Alphabet Stock Soars
NoneSAN DIEGO , Dec. 10, 2024 /PRNewswire/ -- Realty Income Corporation ((Realty Income, NYSE: O ), The Monthly Dividend Company ® , today announced it has declared an increase in the company's common stock monthly cash dividend to $0.2640 per share from $0.2635 per share. The dividend is payable on January 15, 2025 , to stockholders of record as of January 2, 2025 . This is the 128 th dividend increase since Realty Income's listing on the NYSE in 1994. The new monthly dividend represents an annualized dividend amount of $3.168 per share as compared to the prior annualized dividend amount of $3.162 per share. "Throughout our 55-year history, Realty Income has declared 654 consecutive monthly dividends," said Sumit Roy , Realty Income's President and Chief Executive Officer. "Today's declaration represents the 109 th consecutive quarter that we have declared a dividend increase since our 1994 NYSE listing, demonstrating our commitment to providing stockholders a dependable monthly dividend that increases over time." About Realty Income Realty Income O , an S&P 500 company, is real estate partner to the world's leading companies. Founded in 1969, we invest in diversified commercial real estate and have a portfolio of over 15,450 properties in all 50 U.S. states, the U.K., and six other countries in Europe . We are known as "The Monthly Dividend Company ® ," and have a mission to invest in people and places to deliver dependable monthly dividends that increase over time. Since our founding, we have declared 654 consecutive monthly dividends and are a member of the S&P 500 Dividend Aristocrats ® index for having increased our dividend for the last 30 consecutive years. Additional information about the company can be found at www.realtyincome.com . Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Exchange Act of 1934, as amended. When used in this press release, the words "estimated," "anticipated," "expect," "believe," "intend," "continue," "should," "may," "likely," "plans," and similar expressions are intended to identify forward-looking statements. Forward-looking statements include discussions of our business and portfolio; cash flows; the intentions of management; and dividends, including the amount, timing and payment of dividends related thereto. Forward-looking statements are subject to risks, uncertainties, and assumptions about us, which may cause our actual future results to differ materially from expected results. Some of the factors that could cause actual results to differ materially are, among others, our continued qualification as a real estate investment trust; general domestic and foreign business, economic, or financial conditions; competition; fluctuating interest and currency rates; inflation and its impact on our clients and us; access to debt and equity capital markets and other sources of funding (including the terms and partners of such funding); continued volatility and uncertainty in the credit markets and broader financial markets; other risks inherent in the real estate business including our clients' solvency, client defaults under leases, increased client bankruptcies, potential liability relating to environmental matters, illiquidity of real estate investments, and potential damages from natural disasters; impairments in the value of our real estate assets; changes in domestic and foreign income tax laws and rates; property ownership through joint ventures, partnerships and other arrangements which may limit control of the underlying investments; epidemics or pandemics, including measures taken to limit their spread, the impacts on us, our business, our clients, and the economy generally; the loss of key personnel; the outcome of any legal proceedings to which we are a party or which may occur in the future; acts of terrorism and war; the anticipated benefits from mergers and acquisitions including from the merger with Spirit Realty Capital, Inc.; and those additional risks and factors discussed in our reports filed with the U.S. Securities and Exchange Commission. Readers are cautioned not to place undue reliance on forward-looking statements. Forward-looking statements are not guarantees of future plans and performance and speak only as of the date of this press release. Actual plans and operating results may differ materially from what is expressed or forecasted in this press release and forecasts made in the forward-looking statements discussed in this press release might not materialize. We do not undertake any obligation to update forward-looking statements or publicly release the results of any forward-looking statements that may be made to reflect events or circumstances after the date these statements were made. View original content to download multimedia: https://www.prnewswire.com/news-releases/128th-common-stock-monthly-dividend-increase-declared-by-realty-income-302328137.html SOURCE Realty Income Corporation © 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Boston Scientific EVP Arthur Butcher sells $1.25 million in stockSpecial counsel moves to abandon election interference and classified documents cases against Trump WASHINGTON (AP) — Special counsel Jack Smith moved to abandon two criminal cases against Donald Trump on Monday, acknowledging that Trump’s return to the White House will preclude attempts to federally prosecute him for retaining classified documents or trying to overturn his 2020 election defeat. The decision was inevitable, since longstanding Justice Department policy says sitting presidents cannot face criminal prosecution. Yet it was still a momentous finale to an unprecedented chapter in political and law enforcement history, as federal officials attempted to hold accountable a former president while he was simultaneously running for another term. Trump emerges indisputably victorious, having successfully delayed the investigations through legal maneuvers and then winning reelection despite indictments that described his actions as a threat to the country's constitutional foundations. “I persevered, against all odds, and WON," Trump exulted in a post on Truth Social, his social media website. He also said that “these cases, like all of the other cases I have been forced to go through, are empty and lawless, and should never have been brought.” Israel launches new airstrikes on Lebanon as leaders draw closer to a ceasefire with Hezbollah BEIRUT (AP) — Israel's military launched airstrikes across Lebanon on Monday, unleashing explosions throughout the country and killing at least 31 while Israeli leaders appeared to be closing in on a negotiated ceasefire with the Hezbollah militant group. Israeli strikes hit commercial and residential buildings in Beirut as well as in the port city of Tyre. Military officials said they targeted areas known as Hezbollah strongholds. They issued evacuation orders for Beirut's southern suburbs, and strikes landed across the city, including meters from a Lebanese police base and the city's largest public park. The barrage came as officials indicated they were nearing agreement on a ceasefire, while Israeli Prime Minister Benjamin Netanyahu 's Security Cabinet prepared to discuss an offer on the table. Massive explosions lit up Lebanon's skies with flashes of orange, sending towering plumes of smoke into the air as Israeli airstrikes pounded Beirut’s southern suburbs Monday. The blasts damaged buildings and left shattered glass and debris scattered across nearby streets. No casualties were reported after many residents fled the targeted sites. Some of the strikes landed close to central Beirut and near Christian neighborhoods and other targets where Israel had issued evacuation warnings, including in Tyre and Nabatiyeh province. Israeli airstrikes also hit the northeast Baalbek-Hermel region without warning. What's blocking a ceasefire between Israel and Hezbollah? BEIRUT (AP) — Diplomats and other officials say there have been several sticking points in ceasefire talks to end the war between Israel and the Lebanese militant group Hezbollah, even as conditions for an agreement appear to be ripe. Israel’s military has killed nearly all of the militant group’s top leaders, but it continues to fire missiles into Israel. Tens of thousands of Israelis who were evacuated from the border months ago are pressuring their government to help them go home. And the world wants to stop regional conflict from spreading after more than a year of fighting. Following the latest visit to the region by a U.S. mediator, Israel hit central Beirut over the weekend, and Hezbollah responded with its biggest barrage in weeks as each applied pressure to reach a deal. Israel and Hezbollah have exchanged fire almost daily since the day after Hamas-led militants attacked Israel on Oct. 7, 2023, setting off the war in Gaza. Israel launched a widespread bombardment of Lebanon two months ago, then a ground invasion. More than 3,500 people in Lebanon have been killed, many of them civilians. Thanksgiving Travel Latest: Airport strike, staff shortages and weather could impact holiday travel Airports and highways are expected to be jam-packed during Thanksgiving week, a holiday period likely to end with another record day for air travel in the United States. AAA predicts that nearly 80 million Americans will venture at least 50 miles from home between Tuesday and next Monday, most of them by car. However, travelers could be impacted by ongoing weather challenges and those flying to their destinations could be grounded by delays brought on by airline staffing shortages and an airport service workers strike. Here's the latest: U.S. airlines are preparing for a Thanksgiving holiday rush, and so are the U.S. Postal Service, United Parcel Service and FedEx. Shipping companies will deliver about 2.2 billion packages to homes and businesses across the U.S. from Thanksgiving to Dec. 31, said Satish Jindel, a shipping and logistics expert and president of ShipMatrix. White Florida woman sentenced to 25 years in prison for shooting Black neighbor in lengthy dispute A white Florida woman who fatally shot a Black neighbor through her front door during an ongoing dispute over the neighbor’s boisterous children was sentenced Monday to 25 years in prison for her manslaughter conviction. Susan Lorincz, 60, was convicted in August of killing Ajike “A.J.” Owens, 35, by firing a single shot from her .380-caliber handgun in June 2023. She had faced a maximum of 30 years behind bars. Circuit Judge Robert Hodges opted for a slightly lesser term amid evidence that Lorincz had been abused as a child and had mental health problems. “The shooting was completely unnecessary in this case,” Hodges said during an afternoon hearing. “The shooting, I find, was based more in anger than in fear.” The shooting was the culmination of a long-running argument between the two neighbors over Owens’ children playing in a grassy area near both of their houses in Ocala, about 80 miles (130 kilometers) northwest of Orlando. Prosecutors said Owens had come to Lorincz’s home after her children complained that she had thrown roller skates and an umbrella at them, which Lorincz denied. Trial testimony showed Owens, a mother of four young children, was pounding on Lorincz’s door and yelling, leading Lorincz to claim self-defense in shooting her neighbor. Judge in LA delays until January decision on resentencing Menendez brothers LOS ANGELES (AP) — A judge on Monday delayed until January his decision on whether to resentence Erik and Lyle Menendez for killing their parents in their Beverly Hills mansion 35 years ago, squashing their family’s hope the brothers would be released and home for the holidays. Superior Court Judge Michael Jesic said at the hearing in Los Angeles that he needed time to review 17 boxes of documents and give a new district attorney in Los Angeles County time to weigh in on the case. “I’m not ready to go forward,” Jesic said, setting the hearing for the resentencing request for Jan. 30 instead of Dec. 11 as originally planned. The brothers were scheduled to be seen in court for the first time in decades at the hearing but technical problems prevented them from appearing virtually from a San Diego prison. They were found guilty of murdering Jose and Kitty Menendez in 1989 and sentenced to life in prison without parole. While their defense attorneys argued at trial that they had been sexually abused by their father, prosecutors denied that and accused them of killing their parents for money. In the years that followed, they repeatedly appealed their convictions without success. Supreme Court won’t hear challenge to graphic cigarette warning labels WASHINGTON (AP) — The Supreme Court won’t hear a challenge to a federal requirement that cigarette packages and advertising include graphic images demonstrating the effects of smoking. The high court declined to hear the case in a brief written order handed down Monday. Tobacco company R.J. Reynolds appealed to the high court after the 5th U.S. Circuit Court of Appeals found the warnings do not violate the First Amendment. They include pictures of smoke-damaged lungs, feet blackened by diminished blood flow and a picture of a woman with a large growth on her neck and the caption “WARNING: Smoking causes head and neck cancer.” The company argued the final image, for example, was misleading because a patient would likely go to the doctor before a growth reached that size. Russia reportedly captures a Briton fighting for Ukraine as Russian troops advance Russia's military captured a British national fighting with Ukrainian troops who have occupied part of Russia's Kursk region, according to reports Monday, as Moscow began daylight drone attacks on civilian areas of Ukraine and its ground forces accelerated gains along parts of the front line. The Briton was identified by state news agency Tass and other media as James Scott Rhys Anderson. Tass quoted him as saying that he had served as a signalman in the British army for four years and then joined the International Legion of Ukraine, formed early on in Russia's nearly 3-year-old war against its neighbor. On the battlefield, Ukrainian forces are straining to hold at bay a push by Russia's bigger army at places in the eastern Donetsk region. Russian forces recently have gained ground at “a significantly quicker rate” than they did in the whole of last year, according to the Institute for the Study of War, a Washington think tank. The Russians have detected and are exploiting weaknesses in the Ukrainian defenses, it said in an analysis late Sunday. The war surpassed 1,000 days last week, and the milestone coincided with a significant escalation in hostilities. Judge rejects request to sideline a San Jose State volleyball player on grounds she’s transgender A judge on Monday rejected a request to block a San Jose State women’s volleyball team member from playing in a conference tournament on grounds that she is transgender. The ruling by U.S. Magistrate Judge S. Kato Crews in Denver will allow the player, who has played all season, to compete in the Mountain West Conference women’s championship opening this week in Las Vegas. The ruling comes in a lawsuit filed by nine current players against the Mountain West Conference challenging the league’s policies for allowing transgender players to participate. The players argued that letting her compete was a safety risk and unfair. While some media have reported those and other details, neither San Jose State nor the forfeiting teams have confirmed the school has a trans woman volleyball player. The Associated Press is withholding the player’s name because she has not commented publicly on her gender identity. School officials also have declined an interview request with the player. Crews' ruling referred to the athlete as an “alleged transgender” player and noted that no defendant disputed that the San Jose State roster includes a transgender woman player. So you're gathering with relatives whose politics are different. Here are some tips for the holidays NEW YORK (AP) — There's no place like home for the holidays. And that may not necessarily be a good thing. In the wake of the very contentious and divisive 2024 presidential election, the upcoming celebration of Thanksgiving and the ramp-up of the winter holiday season could be a boon for some — a respite from the events of the larger world in the gathering of family and loved ones. Hours and even days spent with people who have played the largest roles in our lives. Another chapter in a lifetime of memories. That's one scenario. For others, that same period — particularly because of the polarizing presidential campaign — is something to dread. There is the likelihood of disagreements, harsh words, hurt feelings and raised voices looming large. Those who make a study of people and their relationships to each other in an increasingly complex 21st-century say there are choices that those with potentially fraught personal situations can make — things to do and things to avoid — that could help them and their families get through this time with a minimum of open conflict and a chance at getting to the point of the holidays in the first place.T-cell malignancies account for about 10-15% of all lymphoid malignancies, and their treatment often involves chemotherapy, immunotherapy, or stem cell transplantation. These cancers can be particularly challenging due to their heterogeneity and resistance to traditional treatments. LAS VEGAS , Dec. 11, 2024 /PRNewswire/ -- T-cell malignancies are a group of cancers originating from the T-cells, a vital part of the immune system responsible for recognizing and combating foreign invaders. These cancers can develop when T-cells undergo genetic mutations, leading to uncontrolled growth and division. T-cell malignancies are generally categorized into two broad types: T-cell lymphomas and T-cell leukemias. T-cell lymphomas primarily affect the lymphatic system, involving lymph nodes and other lymphoid tissues, while T-cell leukemias impact the blood and bone marrow. These malignancies are often more aggressive and harder to treat than B-cell cancers due to their complex biology and resistance to conventional therapies. Symptoms can vary but typically include enlarged lymph nodes, fever, night sweats, and weight loss. Treatment options include chemotherapy, radiation therapy, and novel therapies like CAR T-cell therapy and targeted therapies, which are advancing the understanding and management of these challenging cancers. DelveInsight has recently released a series of epidemiology-based market reports focusing on T-cell malignancies including Acute Lymphoblastic Leukemia, Peripheral T-cell Lymphoma, Cutaneous T-cell Lymphoma, Anaplastic Large Cell Lymphoma, and Adult T-cell Leukemia/Lymphoma . These reports include a comprehensive understanding of current treatment practices, historical and forecasted patient pool, emerging drugs, market share of individual therapies, and historical and forecasted market size from 2020 to 2034 segmented into 7MM [ the United States , the EU-4 ( Italy , Spain , France , and Germany ), the United Kingdom , and Japan ]. Additionally, the reports feature exhaustive analysis of prominent companies working with their emerging candidates in different stages of clinical development. Let's deep dive into the assessment of these T-cell malignancies markets individually. Acute Lymphocytic Leukemia Market Acute lymphocytic leukemia (ALL), also called acute lymphoblastic leukemia, is a cancer that develops in the blood and bone marrow. It originates from immature white blood cells known as lymphocytes in the bone marrow and is marked by the excessive production of immature cells, referred to as lymphoblasts or leukemic blasts. As the bone marrow fails to produce sufficient red blood cells, healthy white blood cells, and platelets, individuals with ALL are more prone to anemia, frequent infections, and easy bruising or bleeding. Among the 7MM, the US accounted for the highest number of incident cases of acute lymphocytic leukemia. The total incident cases of acute lymphocytic leukemia in the US comprised approximately 6,800 cases in 2023 and are projected to increase during the forecast period. Among the type-specific cases of acute lymphocytic leukemia, B-acute lymphocytic leukemia accounted for nearly 85% of the cases, while T-acute lymphocytic leukemia accounted for nearly 15% in the US. The treatment paradigms of acute lymphocytic leukemia have been revolutionized with the advent of tyrosine kinase inhibitors targeting BCR-ABL1 (GLEEVEC [imatinib mesylate], SPRYCEL [dasatinib], and ICLUSIG [ponatinib]), monoclonal antibodies targeting CD20 (RITUXAN), antibody-drug conjugates targeting CD22 (BESPONSA), bispecific antibodies (BLINCYTO), CD19 chimeric antigen receptor T cell therapy (KYMRIAH and TECARTUS) , and others. As per DelveInsight analysis, in 2023, the market size for acute lymphocytic leukemia across the 7MM was around USD 1.6 billion , with projections indicating further growth by 2034. The United States dominated the market in 2023, contributing approximately USD 1.2 billion . ALL presents a significant market opportunity, with BLINCYTO currently leading the segment. Amgen continues to drive innovation in ALL through its BiTE Technology, receiving FDA approval in June 2024 . Additionally, Amgen is advancing a registration-enabling study to develop a subcutaneous injection formulation of blinatumomab. Acute Lymphocytic Leukemia Pipeline Therapies and Companies Orca-T: Orca Biosystems AUTO1/22: Autolus Therapeutics VENCLEXTA/VENCLYXTO (venetoclax): AbbVie and Roche (Genentech) Daratumumab: J&J Innovative Medicine IMBRUVICA (ibrutinib): Pharmacyclics (an AbbVie Company) JAKAFI (ruxolitinib): Incyte Corporation/Novartis VYXEOS (CPX-351): Jazz Pharmaceuticals Obecabtagene autoleucel (obe-cel): Autolus Therapeutics SNDX-5613 (revumenib): Syndax Pharmaceuticals UCART22: Cellectis ADCT-602: ADC Therapeutics WU-CART-007: Wugen For a comprehensive view of the acute lymphocytic leukemia market, check out the Acute Lymphocytic Leukemia Market Assessment Peripheral T-cell Lymphoma Market Peripheral T-cell lymphoma represents a heterogeneous collection of aggressive lymphomas arising from mature T-cells and natural killer cells, comprising approximately 10–15% of all non-Hodgkin lymphomas globally. PTCL is more prevalent in Asia compared to North America and Europe . PTCL has been reported to account for 25% of all NHL cases in Japan . The increased rate of T-cell lymphomas in Asia is attributed to the low incidence of follicular lymphomas. The total incident cases of PTCL in the 7MM were 26,000 cases in 2023; these cases are estimated to increase by 2034. As more targetable mutations are identified and new targeted therapies are developed, the range of treatment options for patients and oncologists continues to expand. However, with the rapid pace of drug approvals, it is crucial to ensure that adequate supporting data justifies the use of specific therapies in the appropriate treatment settings, whether as adjuvant, consolidation, first-line, or subsequent treatments. Peripheral T-cell lymphoma remains a significant therapeutic challenge due to its aggressive nature, rarity, and high heterogeneity. Conventional chemotherapy for PTCL typically involves anthracycline-based regimens (such as CHOP and EPOCH) or non-anthracycline alternatives (including platinum, etoposide, gemcitabine, and methylprednisolone). While the majority of patients initially undergo chemotherapy, nearly a quarter develop primary refractory disease. Many others relapse even after responding to induction chemotherapy, with a median overall survival of just six months. According to NCCN guidelines, specific PTCL subtypes are also treated with six cycles of CHOP-21 or CHOEP, often combined with involved-site radiation therapy. The FDA has approved several drugs for PTCL treatment, including BELEODAQ (Belinostat, Acrotech Biopharma), ISTODAX (Romidepsin, Celgene), FOLOTYN (Pralatrexate, Acrotech Biopharma), ARRANON (Nelarabine, GlaxoSmithKline), XALKORI (Crizotinib, Pfizer), and ADCETRIS (Brentuximab Vedotin, Seattle Genetics). Until recently, there was no established standard of care for first-line treatment in PTCL, leaving a significant gap in approved therapies. The approval of ADCETRIS in November 2018 by the US FDA has transformed the treatment landscape. ADCETRIS, in combination with chemotherapy, is now the first and only FDA-approved regimen for first-line treatment of adults with previously untreated systemic ALCL or other CD30-expressing PTCL. Notably, its approval came less than two weeks after submission under the FDA's real-time oncology review pilot program. Key players, such as Secura Bio, HUYA Bioscience International, Verastem, Solasia Pharma, Seagen, Dizal Pharmaceutical , and others, are evaluating their lead candidates in different stages of clinical development, respectively. As per the DelveInsight assessment, the total market size in the 7MM for PTCL was estimated to be ~USD 680 million in 2020, which is projected to show positive growth by 2034. This growth of the PTCL market is expected to be mainly driven by increased diagnosed incidence, patient awareness, and a robust clinical pipeline during the forecast period (2024–2034). PTCL Pipeline Therapies and Companies COPIKTRA (duvelisib): Secura Bio Linperlisib (YY-20394): Shanghai YingLi Pharmaceutical Golidocitinib (DZD4205) : Dizal Pharmaceuticals Nanatinostat + Valganciclovir: Viracta Therapeutics Lacutamab/IPH4102: Innate Pharma Sugemalimab (CS1001): CStone Pharmaceuticals AFM13: Affimed Tolinapant (ASTX660): Otsuka Pharmaceutical/Astex Pharmaceuticals AUTO4: Autolus MT-101: Myeloid Therapeutics KEYTRUDA (pembrolizumab): Merck Sharp & Dohme OPDIVO (nivolumab): Bristol Myers Squibb To gain a deeper understanding of the PTCL market, be sure to explore the Peripheral T-cell Lymphoma Market Outlook Cutaneous T-cell Lymphoma Market Cutaneous T-cell lymphomas are rare cancers that predominantly involve the skin. Some types progress slowly within the skin, while others may spread to the blood or lymph nodes. The most prevalent form of CTCL is mycosis fungoides, along with its leukemic variant, Sézary syndrome. Another frequently encountered group includes CD30-positive lymphoproliferative disorders (CD30+ LPDs). In 7MM, the United States accounted for the highest number of incident cases of CTCL, which is 46% of the total incident population of CTCL in 7MM in 2023, as per DelveInsight. In the US, out of all stage-specific cases of CTCL, Stage-IA accounted for the highest number of cases, followed by Stage-IB and Stage-IIB cases in 2023. There is currently no approved first-line therapy for early-stage (I–IIA) cutaneous T-cell lymphoma, highlighting a significant unmet need in this patient population. Treatment decisions for patients with mycosis fungoides and Sézary syndrome, both types of CTCL, are influenced by factors such as the extent of skin involvement, the type of lesions, and whether metastasis is present. Therapies for mycosis fungoides focus on either localized skin treatment or systemic approaches, allowing many patients to achieve long-term remission and maintain normal lives. In contrast, Sézary syndrome, marked by systemic involvement, often requires systemic therapies, either alone or in combination, to improve long-term outcomes. TARGRETIN, ADCETRIS, POTELIGEO, ZOLINZA, and ISTODAX are approved by the US FDA for the treatment of Mycosis Fungoides and Sezary Syndrome. Other systemic therapies such as interferons (alfa and gamma), methotrexate, and other retinoids (acitretin and isotretinoin) also offer clinical benefits but have only been evaluated in small studies. As per DelveInsight analysis, the market size of CTCL in the 7MM is expected to cross USD 780 million by 2034. This growth is mainly driven by advancements in targeted therapies, rising awareness of rare cancers, and increasing research and development investments. The adoption of innovative treatments such as monoclonal antibodies and checkpoint inhibitors, coupled with improved diagnostic technologies, is anticipated to enhance market expansion. Additionally, a growing patient population and supportive regulatory policies will further bolster market growth. CTCL Pipeline Therapies and Companies HyBryte (SGX301): Soligenix KINSELBY (resminostat): 4SC AG Lacutamab: Innate Pharma Explore in-depth for a comprehensive understanding of the Cutaneous T-cell Lymphoma Clinical Trials Anaplastic Large Cell Lymphoma Market Anaplastic large cell lymphoma (ALCL) is a rare subtype of non-Hodgkin lymphoma, characterized by large, irregular lymphoid cells that express the CD30 antigen. ALCL accounts for approximately 1% of all NHL cases and 16% of T-cell lymphomas. ALK-positive ALCL is associated with conditions such as HIV, mycosis fungoides, and pulmonary or inflammatory pseudotumors. In contrast, ALK-negative ALCL is more commonly observed in older individuals and is frequently linked to extranodal disease involvement. As per DelveInsight's analysis, ALCL has a slightly higher incidence in men compared to women. ALK-positive ALCL typically affects children and adolescents, with a median age of 30 years, while ALK-negative ALCL tends to affect older adults, with a median age of 54 years. ALK-positive ALCL carries a better prognosis, with 5-year survival rates of 70% to 90% , compared to 40% to 60% for ALK-negative ALCL. The treatment of ALCL varies based on its subtype and stage. Systemic ALCL is commonly addressed with chemotherapy regimens such as CHOP or CHOEP, showing improved outcomes in ALK-positive cases. The key drugs used for the treatment of anaplastic large cell lymphoma are – Pfizer's XALKORI and Takeda's ADCETRIS. For relapsed or refractory cases, brentuximab vedotin has proven effective. Primary cutaneous ALCL is typically managed through radiation, surgery, or chemotherapy and generally has a good prognosis. Breast implant-associated ALCL is treated by removing the implant, with radiation or chemotherapy added if the disease has spread. The ALCL market is anticipated to witness a substantial positive shift owing to better uptake of existing drugs, the expected market launch of therapies, and raised awareness. Additionally, the ALCL market size is expected to increase due to an increasing diagnosed prevalent population, awareness about the subtype of ALCL (Breast implant-associated ALCL), and an increase in R&D activity, which would essentially boost the commercial success of emerging therapies. Anaplastic Large Cell Lymphoma Pipeline Therapies and Companies AUTO4: Autolus Therapeutics SGN-35T: Seagen To access a complete analysis of the anaplastic large cell lymphoma market, visit Anaplastic Large Cell Lymphoma Market Assessment Adult T-cell Leukemia/Lymphoma Market Adult T-cell Leukemia/Lymphoma (ATLL) is a rare and aggressive malignancy of mature T lymphocytes caused by infection with the human T-cell lymphotropic virus type 1 (HTLV-1). ATLL is classified into four clinical subtypes: acute, lymphomatous, chronic, and smoldering, each with distinct prognoses. The acute and lymphomatous forms are the most aggressive, with a median survival of less than a year without treatment. ATLL commonly affects adults aged 40–60 years and is associated with immunosuppression, hypercalcemia, and frequent involvement of skin, lymph nodes, and bone marrow. The global prevalence varies, but it is estimated that about 5–10% of individuals infected with HTLV-1 develop ATLL after decades of latency. Treatment for ATLL is challenging, as the disease presents with a wide range of clinical manifestations, from chronic to acute forms. First-line therapy often involves combination chemotherapy regimens, such as the CHOP (Cyclophosphamide, Doxorubicin, Vincristine, and Prednisolone) regimen, which has shown effectiveness in treating the aggressive forms of ATLL. For more refractory or relapsed cases, a bone marrow transplant may be considered as a curative option. Additionally, the use of denileukin diftitox, a fusion protein targeting CD25, has been approved for relapsed or refractory ATLL. Newer therapies are exploring the use of targeted agents, including histone deacetylase inhibitors (e.g., romidepsin) and lenalidomide, a potent immune-modulatory drug, to improve outcomes in patients with advanced disease. However, despite these options, ATLL treatment remains an area in urgent need of innovation to improve survival rates and quality of life for patients. The Adult T-cell leukemia/lymphoma market is expected to witness significant growth in the coming years, driven by advancements in diagnostics, therapies, and an increased understanding of the disease. Additionally, innovations in immunotherapies, including monoclonal antibodies, CAR-T cell therapies, and combination regimens, are expected to revolutionize the treatment landscape, offering hope for improved survival rates. Moreover, ongoing research into biomarkers and precision medicine will likely lead to better patient stratification and more effective treatment plans. Overall, the ATLL market is poised for expansion, attracting investments in research and development, clinical trials, and regulatory approvals to meet the growing need for better, more accessible therapies. Adult T-cell Leukemia/Lymphoma Pipeline Therapies and Companies Valemetostat Tosylate: Daiichi Sankyo BEAM-201: Beam Therapeutics Inc. Tolinapant: Astex Pharmaceuticals To delve into the adult T-cell leukemia/lymphoma market landscape in more detail, access the Adult T-cell Leukemia/Lymphoma Market Report Trending Oncology Reports Non-Hodgkin Lymphoma Market Non-Hodgkin Lymphoma Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, market share of the individual therapies, and key Non-Hodgkin lymphoma companies, including Roche, Pfizer, Amgen, Novartis, Teva Pharmaceuticals, Genentech, ACD Therapeutics , among others. Non-Hodgkin Lymphoma Pipeline Non-Hodgkin Lymphoma Pipeline Insight – 2024 report provides comprehensive insights about the pipeline landscape, including clinical and non-clinical stage products, and the key Non-Hodgkin lymphoma companies, including Roche, Pfizer, Amgen, Novartis, Teva Pharmaceuticals, Genentech, ACD Therapeutics , among others. B-Cell Lymphoma Market B-Cell Lymphoma Market Insights, Epidemiology, and Market Forecast – 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key B-cell lymphoma companies, including Vincerx Pharma, Ubix Therapeutics, Biomea Fusion Inc, Shanghai Hengrui Pharmaceutical, BeiGene, Hanmi Pharmaceutical, among others. Diffuse Large B-Cell Lymphoma Market Diffuse Large B-Cell Lymphoma Market Insights, Epidemiology, and Market Forecast – 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key B-cell lymphoma companies, including AbbVie, Genmab, Merck, Roche, Xencor and Janssen, Denovo Biopharma, Calithera Biosciences, IMV, Biogen, Autolus Therapeutics, Allogene Therapeutics, Novartis, Miltenyi Biomedicine, Regeneron Pharmaceuticals, among others. About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve . Contact Us Shruti Thakur info@delveinsight.com +14699457679 www.delveinsight.com Logo: https://mma.prnewswire.com/media/1082265/DelveInsight_Logo.jpg